| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:OXOTREMORINE
CAS:70-22-4
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
Finetech Industry Limited
|
| Tel: |
027-87465837 19945049750 |
| Email: |
sales@finetechnology-ind.com |
| Products Intro: |
Product Name:OXOTREMORINE
CAS:70-22-4
Purity:98% Package:1g,10g,25g,100g,500g,1kg
|
|
| | OXOTREMORINE Basic information |
| Product Name: | OXOTREMORINE | | Synonyms: | 2’-oxopyrrolidino-1-pyrrolidino-4-butyne;oxotremorin;1-(4-(pyrrolidin-1-yl)but-2-ynyl)pyrrolidin-2-one;1-(2-Oxo-pyrrolidin-1-yl)-4-(pyrrolidin-1-yl)-2-butyne;1-(2-Oxopyrrolidin-1-yl)-4-(pyrrolidin-1-yl)-2-butyne;1-[4-(Pyrrolidin-1-yl)-2-butynyl]pyrrolidin-2-one;1-(4-pyrrolidin-1-ylbut-2-ynyl)-2-pyrrolidone;1-(4-(Pyrrolidin-1-yl)but-2-yn-1-yl)pyrrolidin-2-one | | CAS: | 70-22-4 | | MF: | C12H18N2O | | MW: | 206.28 | | EINECS: | 200-728-0 | | Product Categories: | | | Mol File: | 70-22-4.mol |  |
| | OXOTREMORINE Chemical Properties |
| Melting point | <25 °C | | Boiling point | 124 °C0.1 mm Hg(lit.) | | density | 1 g/mL at 25 °C(lit.) | | refractive index | n20/D 1.517(lit.) | | Fp | 113 °C | | storage temp. | 2-8°C | | solubility | H2O: 50 mg/mL | | form | liquid | | pka | 8.29±0.20(Predicted) | | color | clear, light yellow | | Merck | 13,7020 |
| Hazard Codes | T+,C | | Risk Statements | 28-34 | | Safety Statements | 26-36/37/39-45 | | RIDADR | UN 2810 6.1/PG 1 | | WGK Germany | 3 | | RTECS | UY5950100 | | F | 10-23 | | HazardClass | 6.1(a) | | PackingGroup | I | | Toxicity | LD50 ipr-rat: 4400 mg/kg TXAPA9 14,67,69 |
| | OXOTREMORINE Usage And Synthesis |
| Definition | ChEBI: Oxotremorine is a N-alkylpyrrolidine. | | General Description | Oxotremorine [1-(-pyrrolidono)-4-pyrrolidino-2-butyne] has been regarded as a CNS muscarinicstimulant. Its action on the brain produces tremors inexperimental animals. It increases ACh brain levels in ratsup to 40% and has been studied as a drug in the treatment ofAlzheimer disease. Although earlier studies suggested thatthis approach of elevating levels of ACh to treat Alzheimerdisease is useful, this belief was highly disputed by manyresearchers. | | Clinical Use | Nevertheless, oxotremorine, as a cholinergicagonist, facilitates memory storage. These findings haveserved as important leads in the development of agents usefulin treating Alzheimer disease. Although it possessesgroups that do not occur in other highly active muscarinicagents, oxotremorine’s trans conformation shows that distancesbetween possible active centers correspond with (+)-muscarine. | | Safety Profile | Poison by ingestion and intraperitoneal routes. Moderately toxic by intravenous route. When heated to decomposition it emits toxic fumes of NOx. |
| | OXOTREMORINE Preparation Products And Raw materials |
|